Results 61 to 70 of about 441,484 (310)

Design and expression of TolC as a recombinant protein vaccine against Shigella flexneri and evaluation of immunogenic response in mice [PDF]

arXiv, 2023
Background: Shigella is one of the major cause of dysenteric diarrhea, which is known shigelosis. Shigelosis causes 160,000 deaths annually of diarrheal disease in a global scale especially children less than 5 years old. No licensed vaccine is available against shigelosis, therefore, efforts for develop an effective and safe vaccine against shigella ...
arxiv  

Targeted-pig trial on safety and immunogenicity of serum-derived extracellular vesicles enriched fractions obtained from Porcine Respiratory and Reproductive virus infections [PDF]

, 2018
The Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is the etiological agent of one of the most important swine diseases with a significant economic burden worldwide.
Borrás, Francesc E., del Portillo, Hernando A., Fraile Sauce, Lorenzo José, Montaner Tarbes, Sergio Roberto, Montoya, Maria, Novell, Elena, Tarancón, Vicens   +6 more
core   +4 more sources

Immunogenicity Risk Profile of Nanobodies

Frontiers in Immunology, 2021
Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a promising class of therapeutics or in vivo imaging reagents entering the clinic.
Chloé Ackaert, Natalia Smiejkowska, C. Xavier, Yann G. J. Sterckx, S. Denies, B. Stijlemans, Y. Elkrim, N. Devoogdt, V. Caveliers, T. Lahoutte, S. Muyldermans, K. Breckpot, M. Keyaerts   +12 more
semanticscholar   +1 more source

Molecular characterization of a Trichinella spiralis serine proteinase

Veterinary Research, 2020
The aim of this study was to investigate the biological characteristics and functions of a Trichinella spiralis serine proteinase (TsSerp) during larval invasion and development in the host.
Xin Yue, Xiang Yuan Sun, Fang Liu, Chen Xi Hu, Ying Bai, Qi Da Yang, Ruo Dan Liu, Xi Zhang, Jing Cui, Zhong Quan Wang   +9 more
doaj   +1 more source

Immunogenicity of Extracellular Vesicles.

Advances in Materials
Extracellular vesicles (EVs) are promising next-generation therapeutics and drug delivery systems due to demonstrated safety and efficacy in preclinical models and early-stage clinical trials. There is an urgent need to address the immunogenicity of EVs (
Yutian Xia, Jianzhong Zhang, Gang Liu, Joy Wolfram   +3 more
semanticscholar   +1 more source

Assessing the Immunogenicity of Biopharmaceuticals [PDF]

BioDrugs, 2016
Biopharmaceuticals have the potential to raise an immunogenic response in treated individuals, which may impact the efficacy and safety profile of these drugs. As a result, it is essential to evaluate immunogenicity throughout the different phases of the clinical development of a biopharmaceutical, including post-marketing surveillance.
Carlos Pineda, Daniel F. Alvarez, Claudio Carini, Ira Jacobs, Gilberto Castañeda Hernández   +4 more
openaire   +2 more sources

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial [PDF]

, 2018
BackgroundModified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral ...
Chaplin, Paul, De Carli, Sonja, Kreusel, Christian, Lawrence, Steven J, Meyer, Thomas P, Nopora, Katrin, Overton, Edgar Turner, Rosch, Siegfried, Samy, Nathaly, Schnidt, Darja, Wagner, Eva, Weidenthaler, Heinz, Young, Philip   +12 more
core   +3 more sources

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper

Molecular Therapy: Methods & Clinical Development, 2022
Immunogenicity has imposed a challenge to efficacy and safety evaluation of adeno-associated virus (AAV) vector-based gene therapies. Mild to severe adverse events observed in clinical development have been implicated with host immune responses against ...
Tong-yuan Yang, Manuela Braun, Wibke Lembke, Fraser McBlane, John Kamerud, Stephen DeWall, Edit Tarcsa, Xiaodong Fang, Lena Hofer, Uma Kavita, Vijay V. Upreti, Swati Gupta, LiNa Loo, Alison J. Johnson, Rakesh Kantilal Chandode, Kay-Gunnar Stubenrauch, Maya Vinzing, Cindy Q. Xia, Vibha Jawa   +18 more
doaj  

Population-specific design of de-immunized protein biotherapeutics [PDF]

, 2017
Immunogenicity is a major problem during the development of biotherapeutics since it can lead to rapid clearance of the drug and adverse reactions. The challenge for biotherapeutic design is therefore to identify mutants of the protein sequence that minimize immunogenicity in a target population whilst retaining pharmaceutical activity and protein ...
arxiv   +1 more source

Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines : randomized, double-blind study in malaria-naïve adults [PDF]

, 2014
This phase II, randomized, double-blind study evaluated the immunogenicity of RTS, S vaccines containing Adjuvant System AS 01 or AS 02 as compared with non-adjuvanted RTS, S in healthy, malaria-naive adults (NCT00443131).
Ballou, W Ripley, Clement, Frédéric, Cohen, Joe, Jongert, Erik, Leroux-Roels, Geert, Leroux-Roels, Isabel, Lievens, Marc, Moris, Philippe, Ofori-Anyinam, Opokua   +8 more
core   +2 more sources